Evidence map›Paper›PMID 21698354›Full record

ReviewJournal of gastroenterology2011

Fetal liver cell transplantation as a potential alternative to whole liver transplantation?

Michael Oertel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Liver cell therapy: is this the end of the beginning?Cellular and molecular life sciences : CMLS · 2018
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cellular therapy for liver disease.Mayo Clinic proceedings · 2014
    Review
  13. Bioengineered kidneys: new sights on a distant horizon.International urology and nephrology · 2014
    Article
  14. Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.Molecular therapy. Methods & clinical development · 2014
    Article
  15. Article
  16. Article
  17. In utero hepatocellular transplantation in rats.Clinical & developmental immunology · 2013
    Article
  18. Review
  19. Cellular therapy and bioartificial approaches to liver replacement.Current opinion in organ transplantation · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Michael OertelDivision of Gastroenterology and Liver Diseases, Department of Medicine, Marion Bessin Liver Research Center, Albert Einstein College of Medicine of Yeshiva University, Ullmann, Bronx, NY 10461, USA. michael.oertel@einstein.yu.edu
Yeshiva University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because organ shortage is the fundamental limitation of whole liver transplantation, novel therapeutic options, especially the possibility of restoring liver function through cell transplantation, are urgently needed to treat end-stage liver diseases. Groundbreaking in vivo studies have shown that transplanted hepatocytes are capable of repopulating the rodent liver. The two best studied models are the urokinase plasminogen activator (uPA) transgenic mouse and the fumarylacetoacetate hydrolase (FAH)-deficient mouse, in which genetic modifications of the recipient liver provide a tissue environment in which there is extensive liver injury and selection pressure favoring the proliferation and survival of transplanted hepatocytes. Because transplanted hepatocytes do not significantly repopulate the (near-)normal liver, attention has been focused on finding alternative cell types, such as stem or progenitor cells, that have a higher proliferative potential than hepatocytes. Several sources of stem cells or stem-like cells have been identified and their potential to repopulate the recipient liver has been evaluated in certain liver injury models. However, rat fetal liver stem/progenitor cells (FLSPCs) are the only cells identified to date that can effectively repopulate the (near-)normal liver, are morphologically and functionally fully integrated into the recipient liver, and remain viable long-term. Even though primary human fetal liver cells are not likely to be routinely used for clinical liver cell repopulation in the future, using or engineering candidate cells exhibiting the characteristics of FLSPCs suggests a new direction in developing cell transplantation strategies for therapeutic liver replacement. This review will give a brief overview concerning the existing animal models and cell sources that have been used to restore normal liver structure and function, and will focus specifically on the potential of FLSPCs to repopulate the liver.

Indexed as

Liver TransplantationStem Cell TransplantationAnimalsDisease Models, AnimalEmbryonic Stem CellsFetal Stem CellsHematopoietic Stem Cell TransplantationHepatocytesHumansInduced Pluripotent Stem CellsKidney Failure, ChronicLiverMesenchymal Stem Cell Transplantation

Identifiers

PMID21698354
OpenAlexW2049026195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.